ConvaTec Group (LON:CTEC) PT Raised to GBX 281

ConvaTec Group (LON:CTECGet Rating) had its price target increased by equities research analysts at JPMorgan Chase & Co. from GBX 275 ($3.23) to GBX 281 ($3.30) in a research note issued to investors on Friday, MarketBeat reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 21.54% from the company’s previous close.

Several other equities research analysts also recently issued reports on CTEC. Royal Bank of Canada reiterated a “sector perform” rating and issued a GBX 210 ($2.47) target price on shares of ConvaTec Group in a research note on Thursday, August 11th. Berenberg Bank restated a “buy” rating and set a GBX 280 ($3.29) price objective on shares of ConvaTec Group in a research report on Thursday. Finally, Barclays raised their price objective on shares of ConvaTec Group from GBX 290 ($3.41) to GBX 295 ($3.47) and gave the stock an “overweight” rating in a research report on Friday, November 11th.

ConvaTec Group Trading Up 4.5 %

Shares of LON:CTEC opened at GBX 231.20 ($2.72) on Friday. ConvaTec Group has a 52-week low of GBX 165.30 ($1.94) and a 52-week high of GBX 256 ($3.01). The company has a market capitalization of £4.73 billion and a P/E ratio of 7,706.67. The company has a 50-day simple moving average of GBX 215.12 and a 200 day simple moving average of GBX 218.93. The company has a debt-to-equity ratio of 90.81, a quick ratio of 0.96 and a current ratio of 1.49.

Insider Activity

In related news, insider Constantin Coussios bought 9,861 shares of the firm’s stock in a transaction on Friday, September 30th. The shares were purchased at an average price of GBX 205 ($2.41) per share, with a total value of £20,215.05 ($23,754.47).

About ConvaTec Group

(Get Rating)

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes.

Read More

Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.